These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 30924030)

  • 1. Tildrakizumab: A Review in Moderate-to-Severe Plaque Psoriasis.
    Frampton JE
    Am J Clin Dermatol; 2019 Apr; 20(2):295-306. PubMed ID: 30924030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials.
    Reich K; Papp KA; Blauvelt A; Tyring SK; Sinclair R; Thaçi D; Nograles K; Mehta A; Cichanowitz N; Li Q; Liu K; La Rosa C; Green S; Kimball AB
    Lancet; 2017 Jul; 390(10091):276-288. PubMed ID: 28596043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial.
    Papp K; Thaçi D; Reich K; Riedl E; Langley RG; Krueger JG; Gottlieb AB; Nakagawa H; Bowman EP; Mehta A; Li Q; Zhou Y; Shames R
    Br J Dermatol; 2015 Oct; 173(4):930-9. PubMed ID: 26042589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks.
    Reich K; Warren RB; Iversen L; Puig L; Pau-Charles I; Igarashi A; Ohtsuki M; Falqués M; Harmut M; Rozzo S; Lebwohl MG; Cantrell W; Blauvelt A; Thaçi D
    Br J Dermatol; 2020 Mar; 182(3):605-617. PubMed ID: 31218661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 64-week phase 3 study (reSURFACE 1).
    Igarashi A; Nakagawa H; Morita A; Okubo Y; Sano S; Imafuku S; Tada Y; Honma M; Mendelsohn AM; Kawamura M; Ohtsuki M
    J Dermatol; 2021 Jun; 48(6):853-863. PubMed ID: 33630387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tildrakizumab: First Global Approval.
    Markham A
    Drugs; 2018 Jun; 78(8):845-849. PubMed ID: 29752706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 5-year extension of a phase 3 study (reSURFACE 1).
    Imafuku S; Nakagawa H; Igarashi A; Morita A; Okubo Y; Sano S; Tada Y; Nemoto O; Rozzo SJ; Kawamura M; Ohtsuki M
    J Dermatol; 2021 Jun; 48(6):844-852. PubMed ID: 33523513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials.
    Blauvelt A; Reich K; Papp KA; Kimball AB; Gooderham M; Tyring SK; Sinclair R; Thaçi D; Li Q; Cichanowitz N; Green S; La Rosa C
    Br J Dermatol; 2018 Sep; 179(3):615-622. PubMed ID: 29742274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of tildrakizumab for plaque psoriasis with continuous dosing, treatment interruption, dose adjustments and switching from etanercept: results from phase III studies.
    Kimball AB; Papp KA; Reich K; Gooderham M; Li Q; Cichanowitz N; La Rosa C; Blauvelt A
    Br J Dermatol; 2020 Jun; 182(6):1359-1368. PubMed ID: 31487406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risankizumab: A Review in Moderate to Severe Plaque Psoriasis.
    Blair HA
    Drugs; 2020 Aug; 80(12):1235-1245. PubMed ID: 32632826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ixekizumab: A Review in Moderate to Severe Plaque Psoriasis.
    Syed YY
    Am J Clin Dermatol; 2017 Feb; 18(1):147-158. PubMed ID: 28138946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials at weeks 12 and 28.
    Papp KA; Reich K; Blauvelt A; Kimball AB; Gooderham M; Tyring SK; Sinclair R; Thaci D; Li Q; Cichanowitz N; Green S; La Rosa C
    J Eur Acad Dermatol Venereol; 2019 Jun; 33(6):1098-1106. PubMed ID: 30838709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Guselkumab for the treatment of moderate-to-severe plaque psoriasis.
    Yang EJ; Sanchez IM; Beck K; Sekhon S; Wu JJ; Bhutani T
    Expert Rev Clin Pharmacol; 2018 Apr; 11(4):333-344. PubMed ID: 29478344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tildrakizumab efficacy and impact on quality of life up to 52 weeks in patients with moderate-to-severe psoriasis: a pooled analysis of two randomized controlled trials.
    Blauvelt A; Sofen H; Papp K; Gooderham M; Tyring S; Zhao Y; Lowry S; Mendelsohn A; Parno J; Reich K
    J Eur Acad Dermatol Venereol; 2019 Dec; 33(12):2305-2312. PubMed ID: 31407394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tildrakizumab: A Review of Phase II and III Clinical Trials.
    Kolli SS; Gabros SD; Pona A; Cline A; Feldman SR
    Ann Pharmacother; 2019 Apr; 53(4):413-418. PubMed ID: 30345790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tildrakizumab for the treatment of psoriasis.
    Bangert C; Kopp T
    Immunotherapy; 2018 Sep; 10(13):1105-1122. PubMed ID: 30081696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ustekinumab: a review of its use in the management of moderate to severe plaque psoriasis.
    Croxtall JD
    Drugs; 2011 Sep; 71(13):1733-53. PubMed ID: 21902296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Guselkumab: A Review in Moderate to Severe Plaque Psoriasis.
    Al-Salama ZT; Scott LJ
    Am J Clin Dermatol; 2018 Dec; 19(6):907-918. PubMed ID: 30467781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of tildrakizumab (MK-3222), a high affinity, selective anti-IL23p19 monoclonal antibody, on cytochrome P450 metabolism in subjects with moderate to severe psoriasis.
    Khalilieh S; Hussain A; Montgomery D; Levine V; Shaw PM; Bodrug I; Mekokishvili L; Bailey-Smith C; Glasgow XS; Cheng A; Martinho M; Iwamoto M
    Br J Clin Pharmacol; 2018 Oct; 84(10):2292-2302. PubMed ID: 29926968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sustained and continuously improved efficacy of tildrakizumab in patients with moderate-to-severe plaque psoriasis.
    Elewski B; Menter A; Crowley J; Tyring S; Zhao Y; Lowry S; Rozzo S; Mendelsohn AM; Parno J; Gordon K
    J Dermatolog Treat; 2020 Dec; 31(8):763-768. PubMed ID: 31268369
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.